ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0021246 | A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. | indomethacin|{1-[(4-chlorophenyl)carbonyl]-5-methoxy-2-methyl-1H-indol-3-yl}acetic acid|Indometacin-containing product|Indometacin|INDOMETHACIN|Indometacinum|Indometacine|Indomethacin-containing product|1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid|INDO|Indometacina|1-(4-chlorobenzoyl)-5-methoxy- 2-methyl-1-H-indole-3-acetic acid|Indomethacin|Indometacin (substance)|Product containing indometacin (medicinal product)|indometacin|1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- | indomethacin |
C0000820 | Abortion induced to save the life or health of a pregnant woman. (From Dorland, 28th ed) | Therapeutic Abortion Procedure|Therapeutic abortion|Therapeutic abortion procedure (procedure)|Therapeutic Abortions|therapeutic abortion|therapeutic abortions|abortion therapeutic|Abortion, Therapeutic|Abortion, therapeutic|Therapeutic Abortion|abortions therapeutic|Therapeutic abortion procedure, NOS|Therapeutic abortion procedure|Abortions, Therapeutic|Therapeutic termination of pregnancy procedure|Therapeutic abortion NOS | Therapeutic abortion (procedure) |
C0242417 | null | Oxidases|oxidase|oxidases|Substance with oxidase mechanism of action|Substance with oxidase mechanism of action (substance)|Oxidase | Oxidases |
C0227395 | null | rectal mucosa|Rectal mucous membrane structure|mucosa rectum|Rectal mucous membrane structure (body structure)|mucosa rectal|Rectal mucous membrane|Rectal mucosa|Mucosa of rectum | Rectal mucous membrane |
C0036457 | A fatal disease of the nervous system in sheep and goats, characterized by pruritus, debility, and locomotor incoordination. It is caused by proteinaceous infectious particles called PRIONS. | scrapie|Scrapie|Scrapie (disorder)|Rida|rida | Scrapie |
C0020835 | Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. | IgA - Immunoglobulin A|Immunoglobulin IgA|IgA|immunoglobulin a (IgA)|Immunoglobulin A (substance)|immunoglobulin a|Immunoglobulin IgA, NOS|immunoglobulin A|Immunoglobulin A | immunoglobulin A |
C0324373 | The German Shepherd Dog is also known as the Alsatian. It is well proportioned and very strong. The coat most often comes in black with tan, sable or all black. It has a sturdy, muscular, slightly elongated body with a light but solid bone structure. It has round feet with very hard soles. Height: 22-26 inches (55-65 cm.) Weight: 77-85 pounds (35-40 kg.) | German shepherd dog (organism)|Alsatian|German shepherd dog|German Shepherd|German Shepherd Dog | German shepherd dog |
C0026724 | An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa. | MUCOSA|Membranes, Mucous|Mucous membrane, NOS|mucous membrane|Mucosa of organ|Membrane, Mucous|Mucosal Tissue|Mucosal Tissues|Organ mucosa|Mucosal (qualifier value)|Tissue, Mucosal|Mucosa|Mucous membrane|Tunica mucosa|Mucous Membrane|Mucous Membranes|Mucous membrane structure|Mucous membrane structure (body structure)|MM - Mucous membrane|Tissues, Mucosal|mucosa|tunica mucosa|Mucosal | Mucous Membrane |
C0015733 | Excrement from the INTESTINES, containing unabsorbed solids, waste products, secretions, and BACTERIA of the DIGESTIVE SYSTEM. | STOOL|poop|stooling|feces|stools|Fecal|poo|Dung|fecal matter|dung|Feces (substance)|faecal|stool|fecal|faeces|crap|Fecal matter|FECES|Gastrointestinal Tract, Feces|Faecal|Feces|Faeces|Stool | Feces |
C0020852 | The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. | immunoglobulin g|Immunoglobulin G (substance)|Immunoglobulin IgG, NOS|IgG|Immunoglobulin IgG|immunoglobulin g (IgG)|Immunoglobulin G|immunoglobulin G|g immunoglobulins|7S Gamma Globulin|Gamma Globulin, 7S | immunoglobulin G |
C1151619 | Catalysis of the reaction: 2 superoxide + 2 H+ = O2 + hydrogen peroxide. [EC:1.15.1.1, GOC:vw, PMID:15064408] | erythrocuprein|hemocuprein|cytocuprein|SOD|Mn-SOD|superoxide:superoxide oxidoreductase activity|SODF|SOD-3|SOD-1|SODS|SOD-4|superoxide dismutase activity|Fe-SOD|SOD-2 | superoxide dismutase activity |
C0019397 | The portion of chromosome material that remains condensed and is transcriptionally inactive during INTERPHASE. | Chromatin condensed|Heterochromatins|Heterochromatin (substance)|Chromatin, condensed|heterochromatin|Heterochromatin | Heterochromatin |
C0005575 | A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk. | (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid|Coenzyme R|Biotina|(+)-Biotin|Vitamin B7|Biotin (substance)|Vitamin H|Biotin-containing product|coenzyme r|cis-Hexahydro-2-oxo-1H-thieno(3,4)imidazole-4-valeric acid|5-(3-oxo-7-thia-2,4-diazabicyclo[3.3.0]oct-8-yl)pentanoic acid|vitamin H|BIOTIN|Product containing biotin (medicinal product)|vitamin h|cis-(+)-Tetrahydro-2-oxothieno[3,4]imidazoline-4-valeric acid|coenzyme R|cis-Tetrahydro-2-oxothieno(3,4-d)imidazoline-4-valeric acid|Biotin preparation|h vitamin|Biotin|-(+)-Biotin|Biotinum|Biotine|5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid|biotin|1H-Thieno(3,4-d)imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS-(3aalpha,4beta,6aalpha))-|Vitamin B-7|(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid | biotin |
C0017350 | Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity). | Immunoglobulin Gene|Ig Gene|Immunoglobulin Genes|immunoglobulin genes|Ig Genes|Gene, Immunoglobulin|Immunoglobulin gene (substance)|ig genes|Immunoglobulin genes|immunoglobulin gene|Gene, Ig|Genes, Ig|Immunoglobulin gene | Genes, Immunoglobulin |
C0380301 | A GLYCOINOSITOL PHOSPHOLIPID MEMBRANE ANCHOR containing ephrin found in developing tectum. It has been shown to mediate the bundling of cortical axons and repel the axonal growth of retinal ganglia axons. It is found in a variety of adult tissues of BRAIN; HEART; and KIDNEY. | Ephrin-A5|AL-1|REK7 Ligand AL-1|REK7 Ligand AL 1|LERK 7 Protein|AL-1 Protein|RAGS Protein|Repulsive Axon Guidance Signal Protein|LERK-7 Protein|Ephrin A5|AL 1 Protein | Ephrin-A5 |
C0006098 | A collective term for interstitial, intracavity, and surface radiotherapy. It uses small sealed or partly-sealed sources that may be placed on or near the body surface or within a natural body cavity or implanted directly into the tissues. | Radioisotope Brachytherapy|Brachytherapy - action (qualifier value)|Brachytherapy, Radioisotope|Brachytherapy|Brachytherapy, intracavitary|Contact radiation therapy procedure, NOS|radiation brachytherapy|brachytherapy|Internal Radiation Brachytherapy|BRACHYTHERAPY|Brachytherapy procedure, NOS|Brachytherapy - action|brachytherapies|Radiation Brachytherapy|Brachytherapy (procedure)|Radioisotope brachytherapy|Brachytherapy procedure|Curietherapy|implant radiation|Internal Radiation Therapy|Plesiotherapy radiation|Internal Radiation|Contact radiation therapy procedure|implants radiation|internal radiation | Brachytherapy |
C0010422 | A heterogeneous family of water-soluble structural proteins found in cells of the vertebrate lens. The presence of these proteins accounts for the transparency of the lens. The family is composed of four major groups, alpha, beta, gamma, and delta, and several minor groups, which are classed on the basis of size, charge, immunological properties, and vertebrate source. Alpha, beta, and delta crystallins occur in avian and reptilian lenses, while alpha, beta, and gamma crystallins occur in all other lenses. | Crystallin, NOS|Proteins, Lens|Crystallin|Crystallin (substance)|Lens Proteins|crystallin | Crystallins |
C0023317 | A transparent, biconvex structure of the EYE, enclosed in a capsule and situated behind the IRIS and in front of the vitreous humor (VITREOUS BODY). It is slightly overlapped at its margin by the ciliary processes. Adaptation by the CILIARY BODY is crucial for OCULAR ACCOMMODATION. | Lens|Crystalline lens, NOS|Lens structure|Ocular lens|Crystalline Lens|eye lens|Lens, Crystalline|lens (eye)|Lens, Eye|Lens, NOS|Eye Lens|ocular lens|Structure of lens of eye (body structure)|Lens clear|EYE, LENS|crystalline lens|Crystalline lens|lens ocular|Structure of lens of eye|lens eye|lens|Lens of eye|Ocular Lens|Lens of Eye|LENS | Lens, Crystalline |
C0019644 | Linker Histone H1 interacts with DNA between nucleosome units in mediating chromatin compaction into higher order structures. Histones are basic nuclear proteins responsible for the nucleosome structure of eukaryotic chromatin. Repeating nucleosome units contain two molecules each of core Histones H2A, H2B, H3, and H4 that form an octamer complex around which approximately 146 base pairs of DNA is wrapped. (NCI) | Histone H1 | Histone H1 |
C0016904 | The most common inhibitory neurotransmitter in the central nervous system. | piperidinic acid|Aminalone|γ-aminobutanoic acid|gamma-aminobutyric acid|.gamma.-aminobutyric Acid|4-aminobutanoic acid|.GAMMA.-AMINOBUTYRIC ACID|gamma-Aminobutyric Acid|γ-Aminobuttersäure|GABA - gamma-aminobutyric acid|γ-aminobutyric acid|GAMMA-AMINOBUTYRIC ACID|piperidic acid|gamma aminobutyric acid|Butanoic acid, 4-amino-|4-Aminobutanoic Acid|Aminalon|4Abu|4 Aminobutanoic Acid|gamma-aminobutyric acid (GABA)|Gamma-aminobutyric acid|4-Aminobutyric Acid|gamma-Aminobutyric acid|4 Aminobutyric Acid|ω-aminobutyric acid|γ-amino-n-butyric acid|Gamma-aminobutyric acid (substance)|Gamma-Aminobutyric Acid|aminalon|gamma Aminobutyric Acid|4-aminobutyric acid|GABA|Piperidic Acid | gamma-aminobutyric acid |
C0147080 | A family of neutral serine proteases with TRYPSIN-like activity. Tryptases are primarily found in the SECRETORY GRANULES of MAST CELLS and are released during mast cell degranulation. | lung tryptase|mast cell protease II|EC 3.4.21.59|Tryptase|Tryptase (substance)|mast cell tryptase|Tryptases|tryptase|tryptase mast cell | TRYPTASE |
C1257901 | A class of receptors that are activated by the action of PROTEINASES. The most notable examples are the THROMBIN RECEPTORS. The receptors contain cryptic ligands that are exposed upon the selective proteolysis of specific N-terminal cleavage sites. | Proteinase Activated Receptors|Protease Activated Receptors|Endopeptidase Activated Receptors|Receptors, Proteinase Activated|Receptors, Endopeptidase-Activated|Proteinase-Activated Receptors|Endopeptidase-Activated Receptors|Receptors, Protease-Activated|Protease-Activated Receptors | Receptors, Proteinase-Activated |
C0006931 | An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS. | Capsaicin (substance)|Capsaicina|N-(4-hydroxy-3-methoxyphenylmethyl) -8-Methyl-6-Nonenamide|CAPSAICIN|8-Methyl-N-Vanillyl-6-Nonenamide|Isodecenoic acid vanillylamide|Product containing capsaicin (medicinal product)|Capsaicin|Capsaicine|(E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide|capsaicine|8 Methyl N Vanillyl 6 Nonenamide|6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-|(E)-N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide|Capsaicin-containing product|trans-8-Methyl-N-vanillyl-6-nonenamide|capsaicin|(E)-8-Methyl-N-vanillyl-6-nonenamide | capsaicin |
C1155266 | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, GOC:mtg_15nov05, ISBN:0198506732] | inflammatory responses|Inflammation Process|inflammatory response|Inflammation Process, Multicellular | Inflammatory Response |
C0015020 | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester)|Amifostine (substance)|Amifostinum|Amifostine|Product containing amifostine (medicinal product)|Amifostine-containing product|APAETP|amifostine|AMIFOSTINE|Amifostina | amifostine |
C0015020 | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Ethanethiol, 2-((3-aminopropyl)amino)-, dihydrogen phosphate (ester)|Amifostine (substance)|Amifostinum|Amifostine|Product containing amifostine (medicinal product)|Amifostine-containing product|APAETP|amifostine|AMIFOSTINE|Amifostina | amifostine |
C0220896 | Denotes the inhabitants of Poland, a person from there, or their descendants elsewhere. | polished|POLISH|Polish|polishing|polish | Polish population |
C1257890 | Individuals classified according to their sex, racial origin, religion, common place of living, financial or social status, or some other cultural or behavioral attribute. (UMLS, 2003) | Population|population group|group populations|population|groups population|Group|Groups, Population|Group (social concept)|Subpopulation|Population Group|Population Groups|Group, Population|population groups | Population Group |
C0077938 | null | acid ursolic|ursolic acid|URSOLIC ACID|(3 beta)-3-hydroxyurs-12-en-28-oic acid | ursolic acid |
C0028066 | A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | Nifedipine|nifedipine|NIFEdipine|3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester|Nifedipino|Nifedipinum|Nifedipine (substance)|NIFEDIPINE|Product containing nifedipine (medicinal product)|4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester|Nifedipine-containing product | nifedipine |
C0028066 | A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. | Nifedipine|nifedipine|NIFEdipine|3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, dimethyl ester|Nifedipino|Nifedipinum|Nifedipine (substance)|NIFEDIPINE|Product containing nifedipine (medicinal product)|4-(2'-Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsäuredimethylester|Nifedipine-containing product | nifedipine |
C0013030 | One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. | Dopamine (substance)|4-(2-aminoethyl)catechol|3,4 Dihydroxyphenethylamine|DOPamine|4-(2-aminoethyl)pyrocatechol|DOPAMINE|2-(3,4-dihydroxyphenyl)ethylamine|Oxytyramine|3,4-Dihydroxyphenethylamine|4-(2-Aminoethyl)benzene-1,2-diol|4-(2-aminoethyl)-1,2-benzenediol|3-Hydroxytyramine|Dopamine|Hydroxytyramine|4-(2-Aminoethyl)-1,2-benzenediol|Dopamine preparation|Product containing dopamine (medicinal product)|1,2-Benzenediol, 4-(2-aminoethyl)-|Dopamine-containing product|dopamine|Dopamina|Dopaminum | dopamine |
C0074554 | A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL. | Simvastatin-containing product|Product containing simvastatin (medicinal product)|Simvastatin (substance)|simvastatin product|simvastatin|[1S-[1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta]]-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2,2-dimethylbutanoate|Simvastatine|Simvastatina|Simvastatin|SIMVASTATIN|2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one|Simvastatinum | simvastatin |
C0682460 | null | sarcoma virus | sarcoma virus |
C0038317 | A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed) | Steroid-containing product|Steroids|steroid|Steroid, NOS|Steroid Compound|Product containing steroid (product)|steroids|Steroid (substance)|Steroid | Steroids |
C0082608 | A synthetic lipid-lowering agent with antilipidemic and potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated antigen-presenting cells such as human vascular endothelial cells. Due to its anti-inflammatory effects mediated by alterations of lipid metabolism, fluvastatin may possess chemopreventive and therapeutic antineoplastic properties. | fluvastatine|7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate|fluvastatina|6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, (3R,5S,6E)-|Product containing fluvastatin (medicinal product)|FLUVASTATIN|fluvastatin|Fluvastatin|fluvastatinum|Fluvastatin-containing product|Fluvastatin (substance) | fluvastatin |
C0026399 | A replication-defective murine sarcoma virus (SARCOMA VIRUSES, MURINE) isolated from a rhabdomyosarcoma by Moloney in 1966. | Virus, Moloney Sarcoma|MoMSV|Moloney Sarcoma Virus|Moloney murine sarcoma virus (organism)|Moloney murine sarcoma virus MuSV|Moloney Murine Sarcoma Virus|MMSV|Sarcoma Virus, Moloney|Murine sarcoma virus|Moloney murine sarcoma virus|MoMuSV | Moloney murine sarcoma virus |
C0026162 | Native, inorganic or fossilized organic substances having a definite chemical composition and formed by inorganic reactions. They may occur as individual crystals or may be disseminated in some other mineral or rock. (Grant & Hackh's Chemical Dictionary, 5th ed; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) | minerals|Mineral (substance)|Mineral, NOS|mineral|Minerals|MINERALS|Mineral | Minerals |
C0032042 | Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. | fake drug|Placebo|PLCB|Placebo (Medicine)|placebos|Sham Treatment|sham treatment|placebo therapy|Placebos|placebo|Placebos (Medicine)|sham therapy | Placebos |
C0029433 | The process of bone formation. Histogenesis of bone including ossification. | Bone Formation|Osteogenesis, NOS|ossifications|bone formation|bone biosynthesis|Bone formation|Bone formation, function (observable entity)|ossification|formation bone|Bone formation, NOS|Osteogenesis|Ossifications|osteogenesis|Ossification|Ossification, NOS|Bone formation, function | Osteogenesis |
C0082608 | A synthetic lipid-lowering agent with antilipidemic and potential antineoplastic properties. Fluvastatin competitively inhibits hepatic 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses through the suppression of MHC II (major histocompatibility complex II) on interferon gamma-stimulated antigen-presenting cells such as human vascular endothelial cells. Due to its anti-inflammatory effects mediated by alterations of lipid metabolism, fluvastatin may possess chemopreventive and therapeutic antineoplastic properties. | fluvastatine|7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate|fluvastatina|6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, (3R,5S,6E)-|Product containing fluvastatin (medicinal product)|FLUVASTATIN|fluvastatin|Fluvastatin|fluvastatinum|Fluvastatin-containing product|Fluvastatin (substance) | fluvastatin |
C0162781 | Low-molecular-weight end products, probably malondialdehyde, that are formed during the decomposition of lipid peroxidation products. These compounds react with thiobarbituric acid to form a fluorescent red adduct. | tbars|TBARs | Thiobarbituric Acid Reactive Substances |
C0039654 | A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA. | Phorbol Myristate Acetate|Myristate Acetate, Phorbol|TPA|12 Myristoyl 13 acetylphorbol|Phorbol 13-Acetate, 12-O-Tetradecanoyl|12-Myristoyl-13-acetylphorbol|12-O-tetradecanoylphorbol-13-acetate|PMA (phorbol myristate acetate)|12 O Tetradecanoyl Phorbol 13 Acetate|Tetradecanoylphorbol Acetate|PMA|13-Acetate, 12-O-Tetradecanoyl Phorbol|12-O-Tetradecanoyl Phorbol 13-Acetate|PHORBOL 12-MYRISTATE 13-ACETATE DIESTER|Tetradecanoic acid, 9a-(acetyloxy)-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1H-cyclopropa(3,4)benz(1,2-e)azulen-9-yl ester, (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9beta,9aalpha))-|Acetate, Phorbol Myristate|TPA (tetradecanoylphorbol acetate)|Acetate, Tetradecanoylphorbol|tetradecanoylphorbol acetate|TPA (Phorbol Ester) | Tetradecanoylphorbol Acetate |
C0003286 | Drugs used to prevent SEIZURES or reduce their severity. | anticonvulsant drugs|Agents, Anticonvulsive|Anticonvulsant Agents|Anticonvulsant, NOS|Anticonvulsant (substance)|Drugs, Anticonvulsive|Anticonvulsants|Anticonvulsant agent|anticonvulsant drug|anticonvulsive drugs|Anticonvulsant Agent|Medicinal product acting as anticonvulsant agent (product)|Anticonvulsant Drugs|anticonvulsant|Anticonvulsant|anticonvulsants|ANTICONVULSANTS|Anticonvulsive Drugs|Anticonvulsive Agents|Drugs, Anticonvulsant|Anti-seizure agent | Anticonvulsants |
C0016365 | The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. | FLUOXETINE|Fluoxetine (substance)|Fluoxetine|(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine|FLUoxetine|fluoxetine|Fluoxetin|Product containing fluoxetine (medicinal product)|FLUOX|N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine|(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine|fluoxetin|Fluoxetine-containing product|Fluoxétine|N-methyl-gamma-(4-(trifluoromethyl) -phenoxy)-benzenepropanamine|Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-|Fluoxetina|Fluoxetinum | fluoxetine |
C0016365 | The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. | FLUOXETINE|Fluoxetine (substance)|Fluoxetine|(+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-P-tolyl)oxy)propylamine|FLUoxetine|fluoxetine|Fluoxetin|Product containing fluoxetine (medicinal product)|FLUOX|N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine|(+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine|fluoxetin|Fluoxetine-containing product|Fluoxétine|N-methyl-gamma-(4-(trifluoromethyl) -phenoxy)-benzenepropanamine|Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-|Fluoxetina|Fluoxetinum | fluoxetine |
C0162758 | Compounds that specifically inhibit the reuptake of serotonin in the brain. | Inhibitors, Serotonin Reuptake|SEROTONIN UPTAKE INHIBITORS|Uptake Inhibitors, 5-Hydroxytryptamine|Substance with serotonin uptake inhibitor mechanism of action (substance)|Inhibitors, Serotonin Uptake|Inhibitors, 5-HT Uptake|Serotonin Uptake Inhibitors|5-Hydroxytryptamine Uptake Inhibitors|Uptake Inhibitors, Serotonin|Serotonin Reuptake Inhibitors|Uptake Inhibitors, 5 Hydroxytryptamine|Inhibitors, 5-Hydroxytryptamine Uptake|5-HT Uptake Inhibitors|inhibitors serotonin|Reuptake Inhibitors, Serotonin|Uptake Inhibitors, 5 HT|serotonin reuptake inhibitors|5 HT Uptake Inhibitors|5-hydroxytryptamine uptake inhibitors|Serotonin uptake inhibitor, NOS|Inhibitors, 5 HT Uptake|5 Hydroxytryptamine Uptake Inhibitors|Uptake Inhibitors, 5-HT|serotonin uptake inhibitor|serotonin reuptake inhibitor|inhibitors reuptake serotonin|serotonin uptake inhibitors|Inhibitors, 5 Hydroxytryptamine Uptake|serotonin inhibitor|Serotonin uptake inhibitor|Serotonin uptake inhibitors | Serotonin Uptake Inhibitors |
C0031412 | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | phenobarbital|Phenobarbital|PHENOBARBITAL|5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione|Phenylbarbital|5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione|Phenylethylbarbitursäure|Fenobarbital|Phenylethylbarbituric Acid|2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-|Phenobarbitone|5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione|5-Phenyl-5-ethylbarbituric acid|PHENO|Phenobarbitol|Acid, Phenylethylbarbituric|PHENobarbital|Phenobarbituric Acid|phenobarbitone|5-Ethyl-5-phenylbarbituric acid|Phenobarbital-containing product|Phenylethylmalonylurea|Phenyläthylbarbitursäure|Phenemal|Phenylethylbarbiturate|Phenobarbital (substance)|5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione|Product containing phenobarbital (medicinal product) | phenobarbital |
C0025260 | Complex mental function having four distinct phases: (1) memorizing or learning, (2) retention, (3) recall, and (4) recognition. Clinically, it is usually subdivided into immediate, recent, and remote memory. | memory function|Memory function|Memory function (observable entity)|Memory, NOS|memory|Memory | Memory |
C0679052 | null | memory processing|process memory|memory process | memory process |
C0004609 | A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission. | beta-(p-Chlorophenyl)-gamma-aminobutyric acid|PCP-GABA|gamma-Amino-beta-(p-chlorophenyl)butyric acid|Chlorophenyl GABA|Baclofen|beta-(Aminomethyl)-4-chlorobenzenepropanoic acid|beta-(4-Chlorophenyl)gaba|Baclophen|Baclofen (substance)|Baclofène|Baclofeno|4-Amino-3-(4-chlorophenyl)butyric acid|beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid|Baclofen-containing product|Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-|Product containing baclofen (medicinal product)|BACLOFEN|baclofen|baclophen|4-Amino-3-(4-chlorophenyl)-butanoic Acid|GABA, Chlorophenyl|beta-(Aminomethyl)-p-chlorohydrocinnamic acid|Baclofenum|beta-(p-Chlorophenyl)-gamma-aminobutyric Acid | baclofen |
C0004609 | A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission. | beta-(p-Chlorophenyl)-gamma-aminobutyric acid|PCP-GABA|gamma-Amino-beta-(p-chlorophenyl)butyric acid|Chlorophenyl GABA|Baclofen|beta-(Aminomethyl)-4-chlorobenzenepropanoic acid|beta-(4-Chlorophenyl)gaba|Baclophen|Baclofen (substance)|Baclofène|Baclofeno|4-Amino-3-(4-chlorophenyl)butyric acid|beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid|Baclofen-containing product|Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-|Product containing baclofen (medicinal product)|BACLOFEN|baclofen|baclophen|4-Amino-3-(4-chlorophenyl)-butanoic Acid|GABA, Chlorophenyl|beta-(Aminomethyl)-p-chlorohydrocinnamic acid|Baclofenum|beta-(p-Chlorophenyl)-gamma-aminobutyric Acid | baclofen |
C0758149 | null | L-AP4 | 2-amino-4-phosphono-propinate |
C0004609 | A GAMMA-AMINOBUTYRIC ACID derivative that is a specific agonist of GABA-B RECEPTORS. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission. | beta-(p-Chlorophenyl)-gamma-aminobutyric acid|PCP-GABA|gamma-Amino-beta-(p-chlorophenyl)butyric acid|Chlorophenyl GABA|Baclofen|beta-(Aminomethyl)-4-chlorobenzenepropanoic acid|beta-(4-Chlorophenyl)gaba|Baclophen|Baclofen (substance)|Baclofène|Baclofeno|4-Amino-3-(4-chlorophenyl)butyric acid|beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid|Baclofen-containing product|Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-|Product containing baclofen (medicinal product)|BACLOFEN|baclofen|baclophen|4-Amino-3-(4-chlorophenyl)-butanoic Acid|GABA, Chlorophenyl|beta-(Aminomethyl)-p-chlorohydrocinnamic acid|Baclofenum|beta-(p-Chlorophenyl)-gamma-aminobutyric Acid | baclofen |
C1510470 | null | Motility (observable entity)|Motility|motility | Motility |
C0206129 | Neurotransmitter receptors located on or near presynaptic terminals or varicosities. Presynaptic receptors which bind transmitter molecules released by the terminal itself are termed AUTORECEPTORS. | Presynaptic Receptor|Presynaptic receptors|Receptor, Presynaptic|Presynaptic Receptors | Receptors, Presynaptic |
C0001471 | A class of cell surface receptors that prefer ADENOSINE to other endogenous PURINES. Purinergic P1 receptors are widespread in the body including the cardiovascular, respiratory, immune, and nervous systems. There are at least two pharmacologically distinguishable types (A1 and A2, or Ri and Ra). | Adenosine Receptors|Purinergic P1 Receptor|P1 Receptor, Purinergic|P1 Purinoceptor|Receptor, Adenosine|P1 Receptors, Purinergic|adenosine receptor|Receptor, Purinergic P1|Receptors, Adenosine|Adenosine Receptor|Purinoceptor, P1|Purinoceptors, P1|P1 Purinoceptors|Purinergic P1 Receptors|adenosine receptors | Receptors, Purinergic P1 |
C0079245 | 10,11-dihydro-5-methyldibenzocyclohepten -5,10-imine; PCP analog, anticonvulsant, and excitatory aminoacid antagonist that acts on the calcium channel site of NMDA receptors; USP lists as a neuroprotectant. | dizocilpine|DIZOCILPINE|Dizocilpine | Dizocilpine |
C0055233 | null | CGS21680 | CGS 21680 |
C0243072 | null | null | derivatives |
C0871828 | null | Neophobia (finding)|Cainophobia|Cainotophobia | Neophobia |
C0026549 | The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. | morphines|Morphia|(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol|Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5alpha,6alpha)-|Morphine (substance)|(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol|(-)-morphine|Morfina|Morphine-containing product|(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol|Morphinum|morphine product|(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol|Morphin|morphine|(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol|Morphium|(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol|Morphine|MORPH|MORPHINE|Product containing morphine (medicinal product) | morphine |
C0025991 | The injection of very small amounts of fluid, often with the aid of a microscope and microsyringes. | microinjections|Microinjections|Microinjection|microinjection | Microinjections |
C0007763 | Four clusters of neurons located deep within the WHITE MATTER of the CEREBELLUM, which are the nucleus dentatus, nucleus emboliformis, nucleus globosus, and nucleus fastigii. | cerebellum nuclei|Cerebellar Nuclei, Deep|Nuclei cerebellares|Cerebellar Nuclei|Nuclei, Cerebellar|Deep cerebellar nuclei|Nucleus, Cerebellar|CNS nuclei (cerebellum)|Nuclei cerebelli|Nuclei, Intracerebellar|Cerebellar nucleus (body structure)|Nuclei, Deep Cerebellar|Intrinsic nuclei of cerebellum|Cerebellar nuclei|Cerebellar nucleus|Nuclei, Central|Nuclei cerebellaris|Central Nuclei|Nucleus, Deep Cerebellar|Central nuclei|Roof nuclei-2|Intracerebellar Nuclei|Deep Cerebellar Nucleus|cerebellar nuclei|Cerebellar Nucleus, Deep|Set of cerebellar nuclei|Cerebellar Nucleus|Nucleus, Intracerebellar|Cerebellar nuclear complex|Deep Cerebellar Nuclei|Intracerebellar nuclei|Central Nucleus|Intracerebellar Nucleus|Nucleus, Central|Nucleus of cerebellum | Cerebellar Nuclei |
C0037322 | A stage of sleep characterized by rapid movements of the eye and low voltage fast pattern EEG. It is usually associated with dreaming. | rapid eye movement sleep|rem sleeping|dream sleep|Fast wave sleep|sleep rem|Sleep, Fast-Wave|active sleep|Rapid eye movement sleep|paradoxical sleep|Fast Wave Sleep|active eye movement sleep|Sleep, Rhombencephalic|desynchronized sleep|dreams sleep|Fast-Wave Sleep|REM sleep|Paradoxical Sleep|Rapid eye movement sleep, function (observable entity)|Rapid eye movement sleep, function|Paradoxical sleep|sleep dream|Sleep, Fast Wave|Desynchronized sleep|rem sleep|Dreaming sleep|Sleep, paradoxical|Sleep, Paradoxical|REM Sleep|dreaming sleep|fast wave sleep|Rhombencephalic Sleep|sleep dreaming|Active sleep|Desynchronised sleep | Sleep, REM |
C0002708 | Almond-shaped group of basal nuclei anterior to the INFERIOR HORN OF THE LATERAL VENTRICLE of the TEMPORAL LOBE. The amygdala is part of the limbic system. | Amygdaloid Nucleus|Amygdaloid body|amygdaloid nuclear complex|Nuclear Complex, Amygdaloid|Archistriatums|Nucleus, Amygdaloid|Amygdaloideums, Corpus|Archistriatum|Complex, Amygdaloid Nuclear|Corpus Amygdaloideum|Amygdalae, Nucleus|Amygdaloid Nuclear Complices|Corpus amygdalae|Amygdala nuclei|Amygdaloid Body|Nucleus amygdalae|Complices, Amygdaloid Nuclear|amygdala|archistriatum|amygdaloid nucleus|Nucleus Amygdalae|Amygdaloid structure|Amygdala|Amygdaloid Nuclear Complex|Nuclear Complices, Amygdaloid|BRAIN, AMYGDALOID BODY|Amygdaloid complex|amygdaloid body|Amygdaloid nuclear groups|Amygdaloideum, Corpus|Amygdaloid structure (body structure)|Corpus amygdaloideum|Amygdaloid Bodies|Amygdaloid nucleus|amygdalas|AMYGDALA|Corpus Amygdaloideums|Amygdaloid nuclear complex | Amygdaloid structure |
C0010132 | A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. | Corticotropin releasing hormone|corticoliberin|Corticotropin-releasing factor|ACTH Releasing Factor|Corticotropin releasing factor (substance)|ACTH releasing factor|CRH - Corticotrophin releasing hormone|corticorelin|Corticotropin Releasing Factor|crh|Corticotropin Releasing Hormone|CRF-41|Corticotrophin releasing hormone|CRF (ACTH)|Corticotropin-Releasing Hormone|CRH (corticotropin releasing hormone)|CRF preparation|Corticotropin-Releasing Factor-41|ACTH-Releasing Factor|corticotropin releasing hormone|corticotropin releasing factor|Corticotropin releasing factor|Corticotropin-Releasing Factor|Corticotropin Releasing Hormone 41|CRF - Corticotrophin releasing factor|Corticotropin releasing factor-containing factor|ACTH-Releasing Hormone|CORTICORELIN|Product containing corticotropin releasing factor (product)|Corticotropin Releasing Factor 41|crf|Corticotrophin releasing factor|Corticotropin-Releasing Hormone-41|ACTH Releasing Hormone|Corticotropin releasing factor preparation|corticotropin-releasing factor|Corticotropin releasing factor (CRF)|corticotropin-releasing hormone|corticotropin RH|CRH|Corticoliberin|CRF | corticotropin-releasing hormone |
C0596040 | compound produced by the mixing of two or more chemicals or a complex that forms when a chemical binds to a biological molecule, such as DNA or a protein. | adducts|adducted|adduct | adduct |
C1516801 | A procedure used in mass spectrometry analysis. Means of delivering nonvolatile analytes into the gas phase for mass analysis. Best used on molecules which are charged in solution or readily accept a charge. Particularly well suited to the analysis of biomolecules. Can be used to probe tertiary structure and non-covalent interactions (from NCSU Mass Spectrometry Facility web site) | ESI|Electrospray Ionization | Electrospray Ionization |
C0007026 | Salts or ions of the theoretical carbonic acid, containing the radical CO2(3-). Carbonates are readily decomposed by acids. The carbonates of the alkali metals are water-soluble; all others are insoluble. (From Grant & Hackh's Chemical Dictionary, 5th ed) | Carbonates|Carbonate (substance)|carbonated|Carbonate|carbonate|carbonates | Carbonates |
C0030903 | A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility. | Pentylenetetrazole|Leptazole|PENTYLENETETRAZOL|pentylenetetrazole|Pentetrazol (substance)|Pentamethylenetetrazole|Pentetrazol|PENTETRAZOL|pentaetrazol|5H-Tetrazolo(1,5-a)azepine, 6,7,8,9-tetrahydro-|Pentylenetetrazol|pentetrazol|Pentetrazole|pentylenetetrazol | pentylenetetrazole |
C0008783 | A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. | Cimetidine (substance)|CIMETIDINE|2-cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine|Cimetidin|N-Cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)guanidine|N''-cyano-N-methyl-N'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine|Cimetidinum|Cimetidina|N-Cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine|cimetidine|N-cyano-N'-methyl-N''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine|Cimetidine-containing product|Product containing cimetidine (medicinal product)|N-cyano-N'-methyl-N''-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine|Guanidine, N''-Cyano-N-Methyl-N'-(2-(((5-Methyl-1H-Imidazol-4-yl)Methyl)Thio)Ethyl)-|Cimetidine|1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine|Cimétidine|Guanidine, N-cyano-N'-methyl-N''-(2-(((5-methyl-1H-imidazol-4-yl)methyl)thio)ethyl)- | cimetidine |
C0009011 | An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses. | 1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one|CLONAZEPAM|Clonazepam|5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one|5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one|Product containing clonazepam (medicinal product)|5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one|2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-|Clonazepam-containing product|clonazepam|Clonazepamum|clonazePAM|Clonazepam (substance) | clonazepam |
C0080356 | fatty acid with anticonvulsant properties. | 2 propylvalerate|Valproate|Valproate (substance)|valproate | valproate |
C0009011 | An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses. | 1,3-dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one|CLONAZEPAM|Clonazepam|5-(2-chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one|5-(2-chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one|Product containing clonazepam (medicinal product)|5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one|2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-|Clonazepam-containing product|clonazepam|Clonazepamum|clonazePAM|Clonazepam (substance) | clonazepam |
C0031412 | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | phenobarbital|Phenobarbital|PHENOBARBITAL|5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione|Phenylbarbital|5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione|Phenylethylbarbitursäure|Fenobarbital|Phenylethylbarbituric Acid|2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-|Phenobarbitone|5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione|5-Phenyl-5-ethylbarbituric acid|PHENO|Phenobarbitol|Acid, Phenylethylbarbituric|PHENobarbital|Phenobarbituric Acid|phenobarbitone|5-Ethyl-5-phenylbarbituric acid|Phenobarbital-containing product|Phenylethylmalonylurea|Phenyläthylbarbitursäure|Phenemal|Phenylethylbarbiturate|Phenobarbital (substance)|5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione|Product containing phenobarbital (medicinal product) | phenobarbital |
C0282597 | A mass spectrometric technique that is used for the analysis of large biomolecules. Analyte molecules are embedded in an excess matrix of small organic molecules that show a high resonant absorption at the laser wavelength used. The matrix absorbs the laser energy, thus inducing a soft disintegration of the sample-matrix mixture into free (gas phase) matrix and analyte molecules and molecular ions. In general, only molecular ions of the analyte molecules are produced, and almost no fragmentation occurs. This makes the method well suited for molecular weight determinations and mixture analysis. | Spectroscopy, Mass, Matrix-Assisted Laser Desorption-Ionization|Mass Spectroscopy, Matrix-Assisted Laser Desorption-Ionization|Mass Spectrometry, Matrix Assisted Laser Desorption Ionization|Matrix Assisted Laser Desorption Ionization Mass Spectrometry|maldi|maldi ms|Laser Desorption-Ionization Mass Spectrometry, Matrix-Assisted|Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry|Matrix-Assisted Laser Desorption Ionization Mass Spectrometry|Mass Spectroscopy, Matrix Assisted Laser Desorption Ionization|MALD-MS|MS-MALD|MALDI|MALDI-MS|MALDI MS|Laser Desorption Ionization Mass Spectrometry, Matrix Assisted|Mass Spectrometry, Matrix-Assisted Laser Desorption-Ionization|matrix assisted laser desorption ionization | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
C0596495 | A mass spectrometry technique used for analysis of nonvolatile compounds such as proteins and macromolecules. The technique involves preparing electrically charged droplets from analyte molecules dissolved in solvent. The electrically charged droplets enter a vacuum chamber where the solvent is evaporated. Evaporation of solvent reduces the droplet size, thereby increasing the coulombic repulsion within the droplet. As the charged droplets get smaller, the excess charge within them causes them to disintegrate and release analyte molecules. The volatilized analyte molecules are then analyzed by mass spectrometry. | Electrospray Ionization Mass Spectrometry|Electrospray ionization mass spectrometry|ESI mass spectrometry|Mass Spectrometry, ESI|Spectrometry, ESI Mass|ESI Mass Spectrometry|electrospray ionization mass spectrometry | Spectrometry, Mass, Electrospray Ionization |
C0036674 | The absence or restriction of the usual external sensory stimuli to which the individual responds. | Sensory deprivation|sensory deprivation|Deprivations, Sensory|Sensory deprivation isolation (finding)|Sensory deprivation isolation|Sensory-perceptual alteration: input deficit|Sensory deprivation, isolation|Deprivation, Sensory|Sensory Deprivations | Sensory Deprivation |
C0023311 | Insertion of an artificial lens to replace the natural CRYSTALLINE LENS after CATARACT EXTRACTION or to supplement the natural lens which is left in place. | lens implantation|IOL - Ins intraocular lens|Intraocular lens implantation|Intraocular Lenses|Implantation of intraocular lens|implants lens|Insertion of lens prosthesis|Lens Implantation, Intraocular|intraocular lenses|Intraocular Lens Implantations|Insertion of prosthetic lens|intraocular lens implantation|Intraocular Lens Implantation|intraocular lens implant|intraocular lense|Insertion of intraocular lens|Insertion of prosthetic intraocular lens (procedure)|Insertion of prosthetic lens [pseudophakos]|Insertion of pseudophakos|Implantations, Intraocular Lens|INTRAOCULAR LENS IMPLANT|lens implant|Insertion of prosthetic intraocular lens|Implantation, Intraocular Lens|Lens implantation|implant lens|implanted lens|Insertion of pseudophakos, not otherwise specified|implants intraocular lens|intraocular lens insertion|Lens Implantations, Intraocular|Insertion of pseudophakos, NOS | intraocular lens implantation procedure |
C0521707 | Partial or complete opacity of the crystalline lens of both eyes that decreases visual acuity and eventually results in blindness. Some cataracts appear in infancy or in childhood, but most develop in older individuals. (Sternberg Diagnostic Surgical Pathology, 3rd ed.) | Bilateral cataracts (disorder)|Cataract, bilateral|Bilateral Cataracts|Cataracts|Bilateral cataract|Bilateral cataracts|bilateral cataracts | Bilateral cataracts (disorder) |
C0489802 | network of capillaries in a particular area or organ of the body. | Capillary Bed|beds capillary|capillary bed|Capillary bed | Capillary Beds |
C0022116 | A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. | Ischemia (disorder)|Ischaemia, NOS|Ischemia|ischaemia|ISCHEMIA|Ischemia, NOS|Ischaemia|Ischemias|ischemia | Ischemia |
C0001480 | An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. | Adenosine 5'-Triphosphoric Acid|Adenosine triphosphate (ATP)|ATP|Adenosine triphosphate (substance)|Adenosine triphosphate|ATP - Adenosine triphosphate|adenosine triphosphate (ATP)|ADT - Adenosine triphosphate|Adenosine 5'-(tetrahydrogen triphosphate)|Adenosine 5'-(Tetrahydrogen Triphosphate)|adenosine triphosphate|ADENOSINE TRIPHOSPHATE|Adenylpyrophosphate|Adenosine Triphosphate|Adenosine 5'-triphosphate|Adenosine-5'-triphosphate | adenosine triphosphate |
C0154884 | null | APMPPE|Acute multifocal placoid pigment epitheliopathy (disorder)|Pigment epitheliopathy, disseminated retinitis and retinochoroiditis|Acute multifocal placoid pigment epitheliopathy|Pigment epitheliopathy, disseminated retinitis AND retinochoroiditis|Acute posterior multifocal placoid pigment epitheliopathy|Disseminated retinitis and retinochoroiditis, pigment epitheliopathy|AMPPE - Acute multifocal placoid pigment epitheliopathy | Acute Posterior Multifocal Placoid Pigment Epitheliopathy |
C0817096 | The upper part of the trunk between the NECK and the ABDOMEN. It contains the chief organs of the circulatory and respiratory systems. (From Stedman, 25th ed) | Thorax|Thoracic (qualifier value)|Thoracic structure|regions thoracic|thoracic region|chest and upper back|thorax|Thoracic|thoraces|CHEST|Thoracic structure (body structure)|thoracics|area thoracic|THORAX|chest region|Chests|thoracic area|chest|thoracic|Thoraces|Chest|Thorace|Thorax, NOS | Chest |
C0025815 | A PREDNISOLONE derivative with similar anti-inflammatory action. | Metipred|6-alpha-Methylprednisolone preparation|6 Methylprednisolone|Methylprednisolonum|(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione|Product containing methylprednisolone (medicinal product)|Methylprednisolone preparation|Methylprednisolone|methylprednisolone|6-Methylprednisolone|Methylprednisolon|methylPREDNISolone|(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione|Methylprednisolone (substance)|6Alpha-Methylprednisolone|Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)-|Methylprednisolone-containing product|Metilprednisolona|delta(1)-6alpha-Methylhydrocortisone|6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione|METHYLPREDNISOLONE|1-dehydro-6α-methylhydrocortisone | methylprednisolone |
C0055345 | null | p-Chlorophenyl-p-chlorobenzyl sulfide (substance)|p-Chlorophenyl-p-chlorobenzyl sulfide|p-chlorobenzyl p-chlorophenyl sulfide | chlorbenside |
C0055345 | null | p-Chlorophenyl-p-chlorobenzyl sulfide (substance)|p-Chlorophenyl-p-chlorobenzyl sulfide|p-chlorobenzyl p-chlorophenyl sulfide | chlorbenside |
C0152309 | A gyrus or ridge on the outer surface of the temporal lobe between the horizontal portion of the fissure of Sylvius and the superior temporal sulcus. | Superior, Gyrus Temporalis|Superior temporal gyrus|Structure of superior temporal gyrus|Temporal Gyrus, Superior|Structure of superior temporal gyrus (body structure)|Superior temporal gyrus structure|Superior Temporal Convolution|Gyrus Temporalis Superior|Superior Temporal Gyrus|Gyrus Temporalis Superiors|Temporalis Superiors, Gyrus|Gyrus, Superior Temporal|Temporalis Superior, Gyrus|Gyrus temporalis superior|Superiors, Gyrus Temporalis | Superior temporal gyrus |
C0033975 | Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) | Disorder, Psychotic|Disorders, Psychotic|atypical psychosis|psychoses|psychotic disorders|psychotic disorder|Psychosis, NOS|PSYCHOSIS|Psychotic disorder, NOS|psychotic disorder nos|Unspecified psychosis|PSYCHOSES|Psychosis|psychosis|Atypical psychosis|Psychotic Disorder|Psychotic disorder (disorder)|Psychotic disorder NOS|ATYPICAL PSYCHOSIS|Psychotic disorder|mental disorder|Atypical Psychoses|Psychosis NOS|Psychotic Disorders|General Psychoses|Psychoses|psychosis nos|Psychosis, atypical | Psychotic Disorders |
C0073393 | A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA. | Risperidone|Risperidone (substance)|4H-Pyrido(1,2-a)pyrimidin-4-one, 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl)ethyl)-6 ,7,8,9-tetrahydro-2-methyl-|Risperidone-containing product|Risperidonum|Risperidona|Product containing risperidone (medicinal product)|risperiDONE|risperidone|RISPERIDONE|Rispéridone | risperidone |
C0171023 | A drug used to treat certain mental disorders. It is also being studied in the treatment of nausea and vomiting caused by some cancer treatments. It is a type of antipsychotic and a type of monoamine antagonist. | Olanzapine (substance)|2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine|Product containing olanzapine (medicinal product)|OLANZapine|olanzapine|OLANZAPINE|Olanzapinum|2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine|Olanzapina|Olanzapin|Olanzapine|Olanzapine-containing product | olanzapine |
C1279146 | null | Entire ankle joint (body structure)|Entire talocrural joint|Entire ankle joint | Entire ankle joint |
C0185160 | null | arthrostomy|Arthrostomy (procedure)|arthrotomy|Arthrostomy|Joint incision|Arthrotomy|Arthrostomy, NOS|Arthrotomy, NOS|Arthrotomy (procedure)|Incision of joint structures | Arthrotomy |
C0343132 | null | Subtotal synovectomy|Partial synovectomy|Partial synovectomy of joint (procedure) | Partial synovectomy of joint |
C0448190 | null | Entire proximal femur (body structure) | Entire proximal femur |
C0018534 | The innermost digit of the foot in PRIMATES. | Big Toes|Hallux; Digitus primus [I]|Toes, Big|First toe|Great toe, NOS|great toe|big toe|Great toe structure (body structure)|Great Toe|Great Toes|Major toe|Toes, Great|Toe, Great|Big toe|Foot Digit 1|Big Toe|Great toe structure|First digit on foot|Hallux|Digitus primus [I] pedis|Hallux structure|first toe|big toes|Toe, Big|Big toe structure|FOOT DIGIT 1|Great toe|First toe, NOS|hallux|Big toe, NOS | Hallux structure |
C0025526 | Any of the five bones between the wrist and the fingers that form the skeleton of the palm. | Metacarpal bone|metacarpus|Bones, Metacarpal|Metacarpal bone structure (body structure)|Os Metacarpale|metacarpals|metacarpal|METACARPAL BONE|Metacarpal bone structure|Metacarpal bone, NOS|Bone structure of metacarpal|bones metacarpal|metacarpal bone|Metacarpals|Metacarpal Bone|Os metacarpale|Metacarpal Bones|Metacarpal|Metacarpal, NOS | Metacarpal bone |
C1269040 | null | Entire nail bed|Entire nail bed (body structure)|Entire subungual skin | Entire nail bed |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.